Duke-NUS and SGH Propose Lymphovenous Bypass: Minimally Invasive Hope for Alzheimer's in Singapore

Singapore Researchers Pioneer Surgical Clearance of Brain Toxins

  • research-publication-news
  • neurodegenerative-diseases
  • alzheimer's-research
  • duke-nus
  • minimally-invasive-surgery
New0 comments

Be one of the first to share your thoughts!

Add your comments now!

Have your say

Engagement level
a black and white photo of various mri images
Photo by National Cancer Institute on Unsplash

Breakthrough Proposal from Singapore's Research Powerhouses

Singapore's medical research landscape is making headlines with a groundbreaking review paper proposing lymphovenous anastomosis (LVA), also known as lymphovenous bypass, as a minimally invasive surgical approach to treat Alzheimer's disease (AD). Published in the March 2026 issue of Plastic and Reconstructive Surgery, the study highlights how enhancing brain lymphatic drainage could clear neurotoxins like amyloid-beta plaques and tau proteins, addressing a key pathological mechanism in AD. 47 102

Led by an interdisciplinary team from Duke-NUS Medical School, Singapore General Hospital (SGH), and the National Neuroscience Institute (NNI), this work underscores Singapore's position as a hub for innovative neuroscience. Duke-NUS, a graduate-level medical school jointly established by Duke University and the National University of Singapore (NUS), brings cutting-edge academic rigor to clinical challenges. The collaboration exemplifies how higher education institutions in Singapore are driving translational research to combat neurodegenerative diseases.

Alzheimer's affects approximately 74,000 Singaporeans as of 2023, with prevalence at 8.8% among those aged 60 and above—a figure expected to rise with the nation's aging population. 61 This proposal arrives at a critical time, offering hope for novel interventions beyond current pharmaceuticals.

The Glymphatic System: Brain's Waste Clearance Pathway

The glymphatic system, first identified in 2012, functions as the brain's pseudolymphatic network, facilitating the removal of metabolic waste during sleep via perivascular spaces and aquaporin-4 channels on astrocytes. In AD, dysfunction in this system leads to accumulation of toxic proteins, exacerbating neurodegeneration. 80

Research shows aging impairs glymphatic flow, with reduced clearance linked to AD risk. Lifestyle factors like exercise and sleep optimization help marginally, but structural interventions like LVA could provide a more direct solution by rerouting lymphatic drainage from deep cervical vessels to veins, promoting continuous passive clearance.

Singaporean researchers at Duke-NUS emphasize that while anti-amyloid drugs like lecanemab slow progression, they target production rather than clearance—LVA fills this gap.

Lymphovenous Anastomosis Explained: A Minimally Invasive Technique

LVA, a staple in plastic and reconstructive surgery for lymphedema, involves microsurgically connecting lymphatic vessels (typically 0.2-0.8mm diameter) to nearby veins using supermicrosurgery tools under magnification. For AD, targets are deep cervical lymphatic vessels (dcLVs) draining the brain, located in the neck near the jugular vein.

Diagram illustrating lymphovenous anastomosis procedure in the neck for Alzheimer's treatment

Step-by-step:

  • Preoperative mapping: Indocyanine green (ICG) lymphography identifies functional lymphatics.
  • Anesthesia: Local or general, outpatient possible.
  • Incision: Small neck incision (2-4cm).
  • Anastomosis: Suture 1-2mm vessels (8-0 to 12-0 nylon), bilateral preferred.
  • Verification: ICG confirms patency.
  • Closure: Sutures removed in 7-10 days.
Recovery is quick, with low complication rates in lymphedema cases. 58

Dr. Khong-Yik Chew, senior consultant at SGH's Plastic Surgery Department, notes LVA's safety profile from thousands of procedures worldwide.

Explore higher ed jobs in Singapore's medical research sector to contribute to such innovations.

Preliminary Evidence Supporting LVA in Alzheimer's

Though early, studies—primarily from China—report promising results. Xie et al. (2023) treated over 200 severe AD patients, noting cognitive stabilization. Li et al. (2024) showed PET/MRI glymphatic improvements in six cases. Chen et al. (2025) observed significant MMSE score gains (P=0.022) in 26 patients, with 60% caregiver-reported benefits. 102

These align with glymphatic impairment theories: MRI metrics like DTI-ALPS correlate with AD severity. LVA's mechanism restores flow without drugs, potentially adjunctive to anti-amyloid therapies.

A pilot trial (NCT06965062) tests cervical LVA in AD, laying groundwork for larger studies. 29

Singapore's Research Ecosystem: Duke-NUS at the Forefront

Duke-NUS Medical School, Singapore's premier graduate medical institution, excels in neuroscience via its Programme in Neuroscience and Behavioral Disorders and GK Goh Centre. Collaborations with SGH (part of SingHealth) and NNI leverage clinical data from Asia's largest neuroscience network.

Lead author Yu-Hsin Yen (Duke-NUS) and co-authors from NNI Neurosurgery highlight interdisciplinary synergy. SGH's plastic surgery expertise, led by Dr. Chew, bridges microsurgery and neurology.

This reflects Singapore's investment in biomedical research, with Duke-NUS ranking among Asia's top for clinical medicine. For aspiring researchers, tips on academic CVs can help enter this field.

Read the full review on PubMed 46

a tall building with a sign on top of it

Photo by Chunjiang on Unsplash

Patient Selection and Measuring Success

The review proposes strict criteria: ages 50-80, mild-moderate AD (MMSE 11-26), biomarker confirmation (CSF Aβ/tau, PET). Exclude comorbidities or advanced disease.

Outcomes via:

  • Cognitive: MoCA, MMSE, RBANS.
  • Imaging: DTI-ALPS MRI, ICG patency.
  • Biomarkers: Serial CSF/plasma levels.
  • Functional: ADL scales, caregiver reports.

Trials need 1-3 year follow-up to assess durability.

Risks, Limitations, and Ethical Considerations

LVA risks: infection (<1%), bleeding, thrombosis—mitigated by antireflux valves. Oncologic safety established; no brain dissemination fears. Limitations: Small studies, mostly Chinese cohorts; causality unproven; sham controls needed.

Singapore's ethics framework, via SingHealth CIRB, ensures rigorous oversight for future trials.

NCT06965062 Trial Details

Future Outlook: Trials and Global Impact

The team calls for multinational RCTs, starting with Singapore-led pilots. Success could extend to Parkinson's, ALS. Singapore's aging crisis (1 in 4 over 65 by 2030) amplifies urgency.

Duke-NUS's role positions it for funding via NMRC, fostering PhD/postdoc opportunities in neuroplastic surgery.Postdoc positions in higher ed.

Duke-NUS and SGH researchers discussing LVA for Alzheimer's

Singapore's Leadership in Neurodegenerative Research

Beyond LVA, Duke-NUS advances AD via single-cell RNA-seq revealing cell-type contributions. 76 NNRIS integrates 200+ experts. This LVA proposal elevates Singapore globally.

For students, Singapore higher ed opportunities abound in biomed.

Career Pathways in Alzheimer's Research

This study opens doors in neurosurgery, plastic surgery, neuroimaging. Duke-NUS offers MD-PhD tracks; SGH residencies blend clinical-academic paths. Check Rate My Professor for insights on faculty.

Actionable: Pursue neuroscience at NUS/Duke-NUS, specialize in microsurgery.

white concrete building under blue sky during daytime

Photo by Galen Crout on Unsplash

Neuroscience News Coverage 47

Conclusion: Hope on the Horizon

The Duke-NUS-SGH LVA proposal redefines AD treatment, targeting clearance for lasting impact. As Singapore tackles dementia's rise, such innovations from its universities promise better outcomes. Stay informed via higher education news; explore higher-ed jobs, rate my professor, career advice, university jobs.

Frequently Asked Questions

🔬What is lymphovenous anastomosis (LVA)?

LVA, or lymphovenous bypass, is a microsurgical technique connecting lymphatic vessels to veins to improve drainage. In Alzheimer's context, it targets cervical vessels to boost glymphatic clearance of neurotoxins.

🧠How does LVA address Alzheimer's disease?

By bypassing impaired brain lymphatics, LVA enhances removal of amyloid-beta and tau, countering glymphatic dysfunction—a key AD factor. Preliminary studies show cognitive gains.

👥Who led the Singapore LVA Alzheimer's study?

Yu-Hsin Yen (Duke-NUS), Min Wei Chen & Jia Xu Lim (NNI), Khong-Yik Chew (SGH). Published in Plastic Reconstr Surg 2026.

📈What are preliminary results of LVA for AD?

Studies report MMSE improvements (P=0.022), PET-confirmed flow gains, 60% symptomatic benefits. Over 200 patients treated safely.

🛡️Is LVA safe for Alzheimer's patients?

Low risks (infection <1%), established in lymphedema. No major AD-specific issues; trials monitor complications.

🏫What role does Duke-NUS play?

Duke-NUS provides neuroscience expertise via its Programme and GK Goh Centre, driving translational research in Singapore.

📊Singapore dementia statistics?

74,000 cases (2023), 8.8% prevalence in 60+. Rising with aging population.

🔮Future trials for LVA in AD?

Pilot NCT06965062; calls for RCTs with multimodal outcomes. Singapore poised to lead.

Patient eligibility for LVA?

Mild-moderate AD, 50-80yo, biomarkers confirmed, no severe comorbidities.

💼How to get involved in Singapore neuroresearch?

Duke-NUS MD-PhD programs, SGH residencies. Visit higher-ed-jobs or university jobs.

🚿Glymphatic system dysfunction in AD?

Aging impairs clearance of waste during sleep, leading to plaques. LVA restores flow.